[ILS-FR-19] Lunch Seminar 19: EVIDENCE OF NEUROPROTECTION IN TOPICAL TREATMENT
- Apr 04 (Fri)
- 12:15 - 13:15
- Room 4 - Tokyo International Forum 7F Hall B7 (2)
- SENJU PHARMACEUTICAL CO.,LTD. / ALLERGAN, INC.
- Chair）Makoto Araie、Chair）Robert Weinreb
- Approaches to neuroprotection include identifying exogenous agents that alleviate neuronal damage or upregulate causative intracellular processes. Several topical anti-glaucoma agents reportedly show neuroprotective effects in vitro, particularly brimonidine that is neuroprotective in several experimental systems. Moreover, topical brimonidine 0.2% better preserved visual field than timolol 0.5% in the randomized double masked Low-pressure Glaucoma Treatment Study (LoGTS). In this symposium, the pathophysiology of optic nerve damage and its amelioration via neuroprotection, particularly with brimonidine, will be addressed.